{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-029639","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2025-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.663314+00:00","generated_at":"2026-05-19T21:46:46.315093+00:00","sec_items":["1.01","1.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Avalo Therapeutics enters $75M ATM equity offering with TD Cowen, terminates prior Oppenheimer facility","bullets":["Entered Sales Agreement with TD Cowen for at-the-market offering of up to $75M in common stock.","Commission to TD Cowen is up to 3% of gross proceeds from sales.","Terminated prior ATM agreement with Oppenheimer (originally $50M) effective June 4, 2025; no penalties.","Offering is made under existing effective S-3 registration statement (File No. 333-271225)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-029639","json":"https://secwatch.observer/filing/0001628280-25-029639.json","markdown":"https://secwatch.observer/filing/0001628280-25-029639.md","text":"https://secwatch.observer/filing/0001628280-25-029639.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828025029639/0001628280-25-029639-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828025029639/avtx-20250603.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T21:46:46.315093+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}